Seaport Res Ptn Weighs in on Hims & Hers Health, Inc.’s Q3 2024 Earnings (NYSE:HIMS)

Hims & Hers Health, Inc. (NYSE:HIMS) – Research analysts at Seaport Res Ptn lifted their Q3 2024 EPS estimates for Hims & Hers Health in a research report issued to clients and investors on Monday, August 5th. Seaport Res Ptn analyst A. Kessler now forecasts that the company will post earnings per share of $0.06 for the quarter, up from their previous estimate of $0.04. Seaport Res Ptn has a “Buy” rating on the stock. The consensus estimate for Hims & Hers Health’s current full-year earnings is $0.20 per share. Seaport Res Ptn also issued estimates for Hims & Hers Health’s Q4 2024 earnings at $0.07 EPS and FY2024 earnings at $0.23 EPS.

Several other brokerages have also issued reports on HIMS. Piper Sandler reiterated a “neutral” rating and issued a $18.00 price target on shares of Hims & Hers Health in a research note on Tuesday. Truist Financial lifted their price target on shares of Hims & Hers Health from $13.00 to $23.00 and gave the company a “hold” rating in a research note on Thursday, July 18th. TD Cowen lifted their price target on shares of Hims & Hers Health from $15.00 to $25.00 and gave the company a “buy” rating in a research note on Thursday, July 11th. Bank of America lifted their price objective on shares of Hims & Hers Health from $22.00 to $26.00 and gave the company a “buy” rating in a research report on Thursday, June 13th. Finally, Jefferies Financial Group lifted their price objective on shares of Hims & Hers Health from $14.00 to $23.00 and gave the company a “hold” rating in a research report on Thursday, June 27th. Seven equities research analysts have rated the stock with a hold rating and eight have issued a buy rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $20.00.

Hims & Hers Health Stock Down 1.2 %

Shares of NYSE:HIMS opened at $15.85 on Wednesday. Hims & Hers Health has a 12 month low of $5.65 and a 12 month high of $25.74. The company’s fifty day simple moving average is $21.19 and its 200 day simple moving average is $15.86. The firm has a market cap of $3.40 billion, a price-to-earnings ratio of -1,585.00 and a beta of 1.08.

Hims & Hers Health (NYSE:HIMS) last posted its earnings results on Monday, August 5th. The company reported $0.06 earnings per share for the quarter, topping the consensus estimate of $0.04 by $0.02. Hims & Hers Health had a negative net margin of 0.24% and a negative return on equity of 0.70%. The company had revenue of $315.65 million for the quarter, compared to analyst estimates of $302.43 million. During the same period last year, the business posted ($0.03) earnings per share. The business’s revenue for the quarter was up 51.8% compared to the same quarter last year.

Institutional Investors Weigh In On Hims & Hers Health

Institutional investors have recently added to or reduced their stakes in the business. Victory Capital Management Inc. boosted its stake in shares of Hims & Hers Health by 23.0% in the 4th quarter. Victory Capital Management Inc. now owns 18,348 shares of the company’s stock valued at $163,000 after purchasing an additional 3,429 shares during the last quarter. Diversify Advisory Services LLC bought a new position in Hims & Hers Health during the first quarter worth $701,000. Forerunner Ventures Management LLC bought a new position in Hims & Hers Health during the fourth quarter worth $86,836,000. Sei Investments Co. boosted its stake in Hims & Hers Health by 206.9% during the first quarter. Sei Investments Co. now owns 56,202 shares of the company’s stock worth $869,000 after acquiring an additional 37,890 shares in the last quarter. Finally, Quantbot Technologies LP boosted its stake in Hims & Hers Health by 3,444.9% during the first quarter. Quantbot Technologies LP now owns 214,677 shares of the company’s stock worth $3,321,000 after acquiring an additional 208,621 shares in the last quarter. 63.52% of the stock is owned by institutional investors.

Insider Activity

In other news, insider Soleil Boughton sold 2,503 shares of the business’s stock in a transaction that occurred on Monday, May 13th. The shares were sold at an average price of $12.33, for a total value of $30,861.99. Following the completion of the transaction, the insider now directly owns 159,357 shares in the company, valued at approximately $1,964,871.81. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. In related news, insider Soleil Boughton sold 2,503 shares of the company’s stock in a transaction that occurred on Monday, May 13th. The shares were sold at an average price of $12.33, for a total transaction of $30,861.99. Following the completion of the transaction, the insider now directly owns 159,357 shares in the company, valued at approximately $1,964,871.81. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, Director Christiane Pendarvis sold 4,000 shares of the company’s stock in a transaction that occurred on Monday, May 13th. The stock was sold at an average price of $12.33, for a total transaction of $49,320.00. Following the transaction, the director now owns 11,210 shares of the company’s stock, valued at $138,219.30. The disclosure for this sale can be found here. In the last ninety days, insiders sold 980,907 shares of company stock worth $19,445,689. 17.71% of the stock is currently owned by corporate insiders.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc operates a telehealth platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers.